24
Participants
Start Date
September 10, 2019
Primary Completion Date
February 1, 2022
Study Completion Date
February 1, 2022
Sodium Oxybate
"Sodium Oxybate will be titrated up weekly by 1.5g nightly dose increments from an initial 4.5g total nightly dose (which could be given in two unequal doses if needed, or one single dose no greater than 4.5g) to an optimal individual dose based on clinical response on RBD symptoms and tolerance, to a maximum nightly dose of 9g (flexible dose period lasting up to 8 weeks). The optimal dose will then be continued for at least 4 weeks (stable dose)."
Placebo
Placebo will be similar in appearance, smell and flavor to the subjects, so that the investigators and participants will be unable to distinguish it from sodium oxybate.
Stanford University, Palo Alto
Collaborators (1)
Jazz Pharmaceuticals
INDUSTRY
Stanford University
OTHER